Jane W. Marsh, Scott R. Curry
下载PDF
{"title":"Therapeutic Approaches for Clostridium difficile Infections","authors":"Jane W. Marsh, Scott R. Curry","doi":"10.1002/9780471729259.mc09a03s30","DOIUrl":null,"url":null,"abstract":"<p>Metronidazole and vancomycin remain the front-line therapies for most <i>Clostridium difficile</i> infections (CDI). However, recurrent CDI occurs in ∼25% of patients, causing significant morbidity and mortality and healthcare costs. For this population, traditional antibiotic therapies fail and new treatment options are greatly needed. The US Food and Drug Administration recently approved fidaxomicin for CDI treatment. This narrow-spectrum antibiotic preserves the normal gut microbiota and shows promise as a treatment for severe and recurrent CDI. Monoclonal antibodies and vaccines directed against toxin are currently in clinical trials and represent alternative, non-antibiotic therapies. Less traditional therapeutic interventions include bacteriotherapy with non-toxigenic <i>C. difficile</i> and fecal transplant. This commentary will provide an overview of current and forthcoming CDI therapies. <i>Curr. Protoc. Microbiol</i>. 30:9A.3.1-9A.3.9. © 2013 by John Wiley & Sons, Inc.</p>","PeriodicalId":39967,"journal":{"name":"Current Protocols in Microbiology","volume":"30 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/9780471729259.mc09a03s30","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/9780471729259.mc09a03s30","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7
引用
批量引用
Abstract
Metronidazole and vancomycin remain the front-line therapies for most Clostridium difficile infections (CDI). However, recurrent CDI occurs in ∼25% of patients, causing significant morbidity and mortality and healthcare costs. For this population, traditional antibiotic therapies fail and new treatment options are greatly needed. The US Food and Drug Administration recently approved fidaxomicin for CDI treatment. This narrow-spectrum antibiotic preserves the normal gut microbiota and shows promise as a treatment for severe and recurrent CDI. Monoclonal antibodies and vaccines directed against toxin are currently in clinical trials and represent alternative, non-antibiotic therapies. Less traditional therapeutic interventions include bacteriotherapy with non-toxigenic C. difficile and fecal transplant. This commentary will provide an overview of current and forthcoming CDI therapies. Curr. Protoc. Microbiol . 30:9A.3.1-9A.3.9. © 2013 by John Wiley & Sons, Inc.
艰难梭菌感染的治疗方法
甲硝唑和万古霉素仍然是大多数艰难梭菌感染(CDI)的一线治疗药物。然而，复发性CDI发生在约25%的患者中，造成显著的发病率和死亡率以及医疗费用。对于这一人群，传统的抗生素治疗无效，迫切需要新的治疗方案。美国食品和药物管理局最近批准非达霉素用于CDI治疗。这种窄谱抗生素保留了正常的肠道微生物群，有望治疗严重和复发性CDI。针对毒素的单克隆抗体和疫苗目前正处于临床试验阶段，是替代的非抗生素疗法。不太传统的治疗干预包括非产毒艰难梭菌的细菌治疗和粪便移植。本评论将提供当前和即将到来的CDI治疗的概述。咕咕叫。Protoc。Microbiol 30:9A.3.1-9A.3.9。©2013 by John Wiley &儿子,Inc。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
